Arrowhead Pharmaceuticals Inc. (ARWR) Announces Proposed 4M Share Common Offering

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced its intention to offer and sell 4,000,000 shares of its common stock in an underwritten offering pursuant to its existing automatic shelf registration statement. All of the shares in the proposed offering are to be sold by Arrowhead. Arrowhead intends to grant the underwriters a 30-day option to purchase up to an additional 600,000 shares of its common stock. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

Goldman Sachs & Co. LLC, Jefferies LLC and Piper Jaffray & Co. are acting as bookrunning managers for the offering, Cantor Fitzgerald & Co. is acting as passive joint bookrunner for the offering and Robert W. Baird & Co. Incorporated and B. Riley FBR, Inc. are acting as co-managers for the offering. Arrowhead intends to use the net proceeds from this offering for general corporate purposes, including working capital, capital expenditures, research and development expenditures and clinical trial expenditures. A portion of the net proceeds may also be used for the acquisition of complementary businesses, products and technologies, or for other strategic purposes.

You May Also Be Interested In

• Denarius Metals acquires 15% stake in Copper Giant, Trafigura invests
• QSE closes $6M private placement with final tranche of $674K
• Andersen prices secondary offering of 4.28M shares at $44 each